From Yahoo Finance: 2025-05-20 16:10:00

BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer Inc. (NYSE:PFE) with a price target of $30 after the company’s exclusive licensing agreement with 3SBio, a Chinese biopharmaceutical company.

The agreement involves the development, manufacturing, and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, currently in clinical trials in China for various cancers. Pfizer (PFE) secured global rights to manufacture and sell the drug, excluding China.

Seigerman noted the strategic move for Pfizer (PFE) to expand its oncology portfolio but highlighted the high costs involved. The company will pay 3SBio $1.25 billion upfront with potential milestone payments up to $4.8 billion. Additionally, 3SBio will receive royalties on sales if the drug is approved.

Seigerman pointed out that Pfizer (PFE) is undervalued compared to U.S. peers, citing operational efficiency and potential clinical developments as reasons for optimism. However, he believes some AI stocks offer greater potential for returns. Check out our report for an AI stock with 100x upside potential.

For more insights on technology stocks and growth opportunities, explore our articles on the 11 Most Promising New Technology Stocks According to Analysts and the 12 Best Growth Stocks to Buy and Hold for the Long Term. Disclosure: None.

Read more: BMO Capital Maintains Buy Rating on Pfizer (PFE) Stock